For your patients with ADHD who are 6 years and older
QuilliChew ER® delivers
Their days may not be consistent but their medication should be.

Unique technology provides continuous release of methylphenidate1
• Lasting improvements in attention and behavior2
Request more information about QuilliChew ER
Click below to sign up to receive more information about QuilliChew ER.
You can also request a visit from a Tris Pharma representative.
ADHD, Attention Deficit Hyperactivity Disorder; ER, extended-release; IR, immediate-release; PK, pharmacokinetic.
References: 1. Kando JC, King TR, Pardo A. A novel, modified-release drug delivery technology containing amphetamine and methylphenidate ion-exchange complexes. Poster presented at: American Psychiatric Association Annual Meeting; May 1-3, 2021. 2. Wigal SB, Childress A, Berry SA, et al. Efficacy and safety of a chewable methylphenidate extended-release tablet in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017;27(8):690-699. 3. QuilliChew ER [package insert]. Tris Pharma, Inc., Monmouth Junction 4. Abbas R, Palumbo D, Walters F, et al. Single-dose pharmacokinetic properties and relative bioavailability of a novel methylphenidate extended-release chewable tablet compared with immediate-release methylphenidate chewable tablet; 2016. Clin Ther. 2016;28(5): 1151-1157.